CardioPROTECTion with Dapagliflozin in Breast Cancer Patients Treated with AnthrAcycline - PROTECTAA TRIAL

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 188 participants.

Also called NCT06304857

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 188 participants (planned count) (from the registry)
Sponsor
4th Military Clinical Hospital with Polyclinic, Poland (from the registry)
Registry
  • NCT NCT06304857
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Poland (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06304857. Randomized; quadruple masking; primary purpose prevention. Start 2024-04-15 (actual); primary completion 2026-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
CardioPROTECTion with Dapagliflozin in Breast Cancer Patients Treated with AnthrAcycline - PROTECTAA TRIAL
Acronym
PROTECTAA
Condition
Breast Cancer
Condition
Heart Failure
Intervention (Drug)
Dapagliflozin
Intervention (Drug)
Placebo
Lead sponsor
4th Military Clinical Hospital with Polyclinic, Poland (class: other)

Record details

Record id
cardio:ct-nct06304857
Content hash
5cad54fb3d636c0efaf2b14ac7321967081e6e4773390bc56b5bfcf44c9db070